Liposomes decorated with Apo2L/TRAIL overcome chemoresistance of human hematologic tumor cells.
De Miguel D, Basanez G, Sánchez D, Galán-Malo P, Marzo I, Larrad L, Naval J, Pardo J, Anel A, Martinez-Lostao L.
Mol Pharm. 2013 Jan 18. [Epub ahead of print]
Protein Kinase C-θ (PKC-θ) in Natural Killer Cell Function and Anti-Tumor Immunity.
Anel A, Aguiló JI, Catalán E, Garaude J, Rathore MG, Pardo J, Villalba M.
Front Immunol. 2012;3:187. doi: 10.3389/fimmu.2012.00187. Epub 2012 Jul 5.
Cytotoxicity of quinone drugs on highly proliferative human leukemia T cells: reactive oxygen species generation and inactive shortened SOD1 isoform implications.
Aguiló JI, Iturralde M, Monleón I, Iñarrea P, Pardo J, Martínez-Lorenzo MJ, Anel A, Alava MA.
Chem Biol Interact. 2012 Jun 25;198(1-3):18-28. doi: 10.1016/j.cbi.2012.05.001. Epub 2012 May 16.
Targeting the Apo2L/TRAIL system for the therapy of autoimmune diseases and cancer.
Martinez-Lostao L, Marzo I, Anel A, Naval J.
Biochem Pharmacol. 2012 Jun 1;83(11):1475-83. doi: 10.1016/j.bcp.2011.12.036. Epub 2012 Jan 2. Review.
APO2L/TRAIL: new insights in the treatment of autoimmune disorders.
Anel A, Martinez-Lostao L.
Recent Pat Inflamm Allergy Drug Discov. 2011 Sep;5(3):184-99. Review.
Phenotypic and functional evaluation of CD3+CD4-CD8- T cells in human CD8 immunodeficiency.
Bernardo I, Mancebo E, Aguiló I, Anel A, Allende LM, Guerra-Vales JM, Ruiz-Contreras J, Serrano A, Talayero P, de la Calle O, Gonzalez-Santesteban C, Paz-Artal E.
Haematologica. 2011 Aug;96(8):1195-203. doi: 10.3324/haematol.2011.041301. Epub 2011 May 5.
